Method of treating graft versus host disease

1. A method for preventing the development of or treating graft versus host disease (GvHD) complications in a human patient undergoing or about to undergo a bone marrow or hematopoietic stem cell transplantation, which method comprises administering, to the human patient, a therapeutically effective amount of a population of cells enriched for STRO-1 + , TNAP + mesenchymal precursor cells (MPCs), or multipotential cells culture-expanded from STRO-1 + , TNAP + MPCs, wherein the cells in the administered population are CD34 − .

2. The method according to claim 1 , wherein the administered population is administered to the human patient prior to undergoing the transplantation.

3. The method according to claim 1 , wherein the bone marrow or hematopoietic stem cell transplantation is an allogeneic transplantation.

4. The method according to claim 1 , wherein the administered population is allogeneic.

5. The methods according to claim 1 , wherein the population is administered systemically.

6. The method according to claim 5 , wherein the population is administered by intravenous injection.

7. The method of claim 1 , wherein the administered population comprises between 0.1×10 6 to 5×10 6 cells.

8. The method of claim 1 , wherein the administered population comprises between 0.3×10 6 to 2×10 6 cells.

9. The method of claim 1 , wherein the administered population comprises between 0.1×10 5 and 0.5×10 6 cells.

10. The method of claim 9 , wherein the administered population comprises about 0.3×10 6 cells.

11. The method of claim 1 , wherein the administered population is administered once weekly or less often.

12. The method according to claim 1 , wherein the human patient is suffering from aplastic anemia, myelofibrosis, or bone marrow failure following chemotherapy and radiation therapy.

13. The method according to claim 1 , further comprising administering an immunosuppressive drug to the human patient.